EA201992570A1 - Составы на основе человеческих антител к rankl, а также способы их применения - Google Patents
Составы на основе человеческих антител к rankl, а также способы их примененияInfo
- Publication number
- EA201992570A1 EA201992570A1 EA201992570A EA201992570A EA201992570A1 EA 201992570 A1 EA201992570 A1 EA 201992570A1 EA 201992570 A EA201992570 A EA 201992570A EA 201992570 A EA201992570 A EA 201992570A EA 201992570 A1 EA201992570 A1 EA 201992570A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- rankl
- ways
- application
- human antibodies
- compositions based
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
В данном документе раскрыты водные фармацевтические составы, содержащие деносумаб или другое человеческое моноклональное антитело к RANKL или его часть, а также характеристики pH, буферных систем и аминокислотных ингибиторов агрегации. Также раскрыты форма выпуска состава для применения, например, в виде одноразового флакона, одноразового шприца или стеклянного контейнера, способы применения составов и изделий для предупреждения или лечения заболеваний и соответствующие наборы.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762492056P | 2017-04-28 | 2017-04-28 | |
PCT/US2018/029728 WO2018200918A1 (en) | 2017-04-28 | 2018-04-27 | Formulations of human anti-rankl antibodies, and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201992570A1 true EA201992570A1 (ru) | 2020-03-20 |
Family
ID=62165668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201992570A EA201992570A1 (ru) | 2017-04-28 | 2018-04-27 | Составы на основе человеческих антител к rankl, а также способы их применения |
Country Status (31)
Country | Link |
---|---|
US (2) | US11192952B2 (ru) |
EP (2) | EP3615066B1 (ru) |
JP (3) | JP7190822B2 (ru) |
KR (1) | KR20190140464A (ru) |
CN (1) | CN110621342A (ru) |
AR (1) | AR111497A1 (ru) |
AU (1) | AU2018260750A1 (ru) |
BR (1) | BR112019022188A2 (ru) |
CA (1) | CA3054165A1 (ru) |
CL (3) | CL2019003032A1 (ru) |
CO (1) | CO2019011463A2 (ru) |
CR (1) | CR20190538A (ru) |
DK (1) | DK3615066T3 (ru) |
EA (1) | EA201992570A1 (ru) |
FI (1) | FI3615066T3 (ru) |
HR (1) | HRP20240167T1 (ru) |
IL (2) | IL293127B1 (ru) |
JO (1) | JOP20190255A1 (ru) |
LT (1) | LT3615066T (ru) |
MA (1) | MA48462A (ru) |
MY (1) | MY202479A (ru) |
PE (1) | PE20200343A1 (ru) |
PH (1) | PH12019502444A1 (ru) |
PL (1) | PL3615066T3 (ru) |
PT (1) | PT3615066T (ru) |
RS (1) | RS65299B1 (ru) |
SG (1) | SG11201909998TA (ru) |
SI (1) | SI3615066T1 (ru) |
TN (2) | TN2021000055A1 (ru) |
UY (1) | UY37707A (ru) |
WO (1) | WO2018200918A1 (ru) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202033216A (zh) * | 2018-11-16 | 2020-09-16 | 南韓商三星Bioepis股份有限公司 | 包含蛋白質的穩定液體組成物 |
CN109374779A (zh) * | 2018-12-17 | 2019-02-22 | 杭州奕安济世生物药业有限公司 | 一种蔗糖含量的快速检测方法 |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
CN111704670B (zh) * | 2020-08-18 | 2020-11-03 | 迈威(上海)生物科技股份有限公司 | 重组抗RANKL抗体IgG2型的二硫键异构体及其纯化方法 |
BR112023022707A2 (pt) * | 2021-05-12 | 2024-01-16 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Molécula de ligação ao antígeno a qual se liga especificamente a rankl e ngf, e seu uso médico |
CA3228269A1 (en) | 2021-08-12 | 2023-02-16 | Amgen Inc. | Antibody formulations |
WO2023092177A1 (en) * | 2021-11-23 | 2023-06-01 | Adalta Limited | Rank-l binding molecules |
WO2023179791A1 (en) * | 2022-03-24 | 2023-09-28 | Angitia Biomedicines Limited | Treatment of musculoskeletal disorders |
WO2024064878A1 (en) | 2022-09-23 | 2024-03-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for the treatment of melanoma |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ547695A (en) | 2001-06-26 | 2008-09-26 | Amgen Fremont Inc | Antibodies to OPGL |
TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
CA2790018C (en) * | 2006-12-21 | 2015-02-03 | Amgen Inc. | Formulations |
US7951368B2 (en) * | 2007-06-25 | 2011-05-31 | Amgen Inc. | Compositions of specific binding agents to hepatocyte growth factor |
AU2009210741A1 (en) * | 2008-02-07 | 2009-08-13 | Amgen Inc. | Stabilized protein compositions |
AR073072A1 (es) | 2008-08-19 | 2010-10-13 | Regeneron Pharma | Anticuerpos humanos para el ligando del activador del receptor de nf-kb (rankl) humano |
US9265834B2 (en) | 2009-03-05 | 2016-02-23 | Ablynx N.V. | Stable formulations of polypeptides and uses thereof |
RU2600847C2 (ru) | 2010-05-10 | 2016-10-27 | Интас Биофармасьютикалс Лимитед | Жидкий состав полипептидов, содержащих fc-домен иммуноглобулина |
EP2433644A1 (en) | 2010-09-22 | 2012-03-28 | IMBA-Institut für Molekulare Biotechnologie GmbH | Breast cancer therapeutics |
SG193964A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
KR101759694B1 (ko) | 2011-10-28 | 2017-07-19 | 인테그리티 바이오, 아이엔씨. | 아미노산을 함유하는 단백질 제제 |
TWI679019B (zh) | 2013-04-29 | 2019-12-11 | 法商賽諾菲公司 | 抗il-4/抗il-13之雙特異性抗體調配物 |
CN103965357B (zh) | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
US20150274819A1 (en) | 2014-03-03 | 2015-10-01 | La Jolla Biologics, Inc. | Stable aqueous recombinant protein formulations |
WO2015169742A1 (en) | 2014-05-07 | 2015-11-12 | Takeda Gmbh | Liquid formulation comprising gm-csf neutralizing compound |
-
2017
- 2017-06-16 JO JOP/2019/0255A patent/JOP20190255A1/ar unknown
-
2018
- 2018-04-27 EP EP18724690.5A patent/EP3615066B1/en active Active
- 2018-04-27 KR KR1020197034225A patent/KR20190140464A/ko active IP Right Grant
- 2018-04-27 DK DK18724690.5T patent/DK3615066T3/da active
- 2018-04-27 US US16/608,375 patent/US11192952B2/en active Active
- 2018-04-27 MY MYPI2019006326A patent/MY202479A/en unknown
- 2018-04-27 TN TNP/2021/000055A patent/TN2021000055A1/en unknown
- 2018-04-27 PE PE2019002120A patent/PE20200343A1/es unknown
- 2018-04-27 IL IL293127A patent/IL293127B1/en unknown
- 2018-04-27 AR ARP180101105A patent/AR111497A1/es unknown
- 2018-04-27 RS RS20240313A patent/RS65299B1/sr unknown
- 2018-04-27 AU AU2018260750A patent/AU2018260750A1/en active Pending
- 2018-04-27 JP JP2018086261A patent/JP7190822B2/ja active Active
- 2018-04-27 MA MA048462A patent/MA48462A/fr unknown
- 2018-04-27 WO PCT/US2018/029728 patent/WO2018200918A1/en active Application Filing
- 2018-04-27 CN CN201880028012.1A patent/CN110621342A/zh active Pending
- 2018-04-27 EP EP22206709.2A patent/EP4190355A1/en active Pending
- 2018-04-27 CR CR20190538A patent/CR20190538A/es unknown
- 2018-04-27 LT LTEPPCT/US2018/029728T patent/LT3615066T/lt unknown
- 2018-04-27 EA EA201992570A patent/EA201992570A1/ru unknown
- 2018-04-27 UY UY0001037707A patent/UY37707A/es unknown
- 2018-04-27 SG SG11201909998T patent/SG11201909998TA/en unknown
- 2018-04-27 TN TNP/2019/000297A patent/TN2019000297A1/en unknown
- 2018-04-27 PL PL18724690.5T patent/PL3615066T3/pl unknown
- 2018-04-27 SI SI201831067T patent/SI3615066T1/sl unknown
- 2018-04-27 HR HRP20240167TT patent/HRP20240167T1/hr unknown
- 2018-04-27 BR BR112019022188-3A patent/BR112019022188A2/pt unknown
- 2018-04-27 FI FIEP18724690.5T patent/FI3615066T3/fi active
- 2018-04-27 CA CA3054165A patent/CA3054165A1/en not_active Abandoned
- 2018-04-27 PT PT187246905T patent/PT3615066T/pt unknown
-
2019
- 2019-08-14 IL IL268704A patent/IL268704B/en unknown
- 2019-10-16 CO CO2019011463A patent/CO2019011463A2/es unknown
- 2019-10-23 CL CL2019003032A patent/CL2019003032A1/es unknown
- 2019-10-28 PH PH12019502444A patent/PH12019502444A1/en unknown
-
2020
- 2020-07-31 CL CL2020002012A patent/CL2020002012A1/es unknown
-
2021
- 2021-11-18 US US17/529,794 patent/US11873343B2/en active Active
-
2022
- 2022-01-14 JP JP2022004150A patent/JP7356525B2/ja active Active
-
2023
- 2023-08-10 JP JP2023130715A patent/JP2023166396A/ja active Pending
- 2023-08-24 CL CL2023002505A patent/CL2023002505A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201992570A1 (ru) | Составы на основе человеческих антител к rankl, а также способы их применения | |
CY1123657T1 (el) | Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1 | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
AR124676A2 (es) | Formulación farmacéutica que comprende una droga biofarmacéutica | |
EA201992377A1 (ru) | Стабильная композиция антитела | |
PE20181805A1 (es) | Composiciones y anticuerpos anti-tim-3 | |
EP4248996A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
NZ719036A (en) | Anti-pdl1 antibody formulations | |
EA200970880A1 (ru) | Стабильные композиции на основе антител | |
NZ743964A (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
EA201790989A1 (ru) | Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации | |
BR112015022210A2 (pt) | formulações farmacêuticas aquosas estáveis, seu uso, artigo de manufatura, métodos de redução da agregação de um anticorpo monoclonal terapêutico e método de produção de uma formulação farmacêutica. | |
EA201500132A1 (ru) | Биспецифические антитела к vegf/ang-2 и их применение для лечения сосудистых глазных заболеваний | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
UA113623C2 (uk) | Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi) | |
CO7270463A2 (es) | Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición | |
EA201892774A1 (ru) | Антитела | |
EA201492186A1 (ru) | СОДЕРЖАЩИЕ АНТИТЕЛА К Dll4 СТАБИЛИЗИРОВАННЫЕ КОМПОЗИЦИИ | |
AU2018249796A1 (en) | Antibody Fc variants for improving blood half-life | |
EA201992626A1 (ru) | Способы и композиции для лечения аллергических заболеваний глаз | |
EA201992324A1 (ru) | Анти-trem2 антитела и способы их применения | |
EA202191990A1 (ru) | Состав терапевтического антитела |